Goldman Sachs
RPRX

Goldman Sachs’s Repros Therapeutics Inc. RPRX Stock Holding History

Goldman Sachs’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-20,600
Closed -$153K – 7716
2015
Q3 		$153K Buy
+20,600
New +$158K ﹤0.01% 6195
2015
Q1 		– Sell
-112,800
Closed -$1.13M – 7648
2014
Q4 		$1.13M Buy
112,800
+64,200
+132% +$547K ﹤0.01% 4436
2014
Q3 		$481K Buy
+48,600
New +$720K ﹤0.01% 5306
2013
Q4 		– Sell
-741,600
Closed -$19.9M – 7067
2013
Q3 		$19.9M Buy
741,600
+360,400
+95% +$7.72M 0.01% 1632
2013
Q2 		$7.03M Buy
+381,200
New +$6.73M ﹤0.01% 2396

Goldman Sachs's RPRX Position: Q1 2018 in Review

Goldman Sachs sold out of Repros Therapeutics Inc. (RPRX) in Q1 2018, closing a stake of 11,147 shares — an estimated $7K sold.

Goldman Sachs first reported a position in RPRX in Q2 2013 and held it in 19 quarters. The position peaked at $4.2M in Q2 2013. 1 fund tracked by Wall St. Rank holds RPRX as of Q1 2018.

  • Goldman Sachs reported no remaining Repros Therapeutics Inc. position as of Q1 2018 after selling out during the quarter.
  • Goldman Sachs sold 11,147 Repros Therapeutics Inc. shares in Q1 2018, an estimated $7K.
  • Goldman Sachs first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 19 quarters.
  • Goldman Sachs's Repros Therapeutics Inc. position peaked at $4.2M in Q2 2013.
  • 1 fund tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2018.

Based on Goldman Sachs's 13F filing for Q1 2018, filed 15 May 2018.